parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 10612

SLC4A4 in dopamine neurons, braak+0.32 (p 0.407) → +0.33 (p 0.393)receipt 10620
SLC4A4 in astrocytes, braak-0.22 (p 0.569) → +0.08 (p 0.838)receipt 10619

receipt 10620: SLC4A4 in dopamine neurons, braak

power: full sample +0.29 (p 0.243, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.31 (p 0.218, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.235, n 18). could be the mix.
skeptic: leave-one-out range +0.23 to +0.48, sign flips 0; without severely affected donors +0.29 (p 0.243, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC4A4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10619: SLC4A4 in astrocytes, braak

power: full sample +0.09 (p 0.735, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.15 (p 0.555, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.14 (p 0.573, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.19, sign flips 3; without severely affected donors +0.09 (p 0.735, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC4A4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts